Neurology

Back to articles

Erenumab may reduce overuse of pain medications for chronic migraines

KEY POINT

Use of once-monthly erenumab (Aimovig—Amgen, Novartis) in patients with chronic migraine who overused medications resulted in a greater reduction in migraine days and acute migraine-specific medication treatment days compared with placebo, according to an analysis published in Neurology.

 

SOURCES

Tepper SJ, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019;[Epub ahead of print].